Chevy Chase Trust Holdings LLC Has $16.24 Million Holdings in Humana Inc. (NYSE:HUM)

Chevy Chase Trust Holdings LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,005 shares of the insurance provider’s stock after selling 1,373 shares during the period. Chevy Chase Trust Holdings LLC owned approximately 0.05% of Humana worth $16,239,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. State Street Corp grew its stake in shares of Humana by 1.0% during the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after purchasing an additional 53,272 shares during the period. FMR LLC grew its stake in shares of Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares during the period. Pzena Investment Management LLC grew its stake in shares of Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after purchasing an additional 187,903 shares during the period. Ontario Teachers Pension Plan Board grew its stake in shares of Humana by 6.5% during the third quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock worth $371,705,000 after purchasing an additional 71,910 shares during the period. Finally, Sanders Capital LLC grew its stake in shares of Humana by 1.0% during the third quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider’s stock worth $370,060,000 after purchasing an additional 11,923 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.32% of the company’s stock.

Humana Stock Performance

HUM opened at $253.61 on Friday. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The firm has a market capitalization of $30.54 billion, a PE ratio of 22.46, a PEG ratio of 2.11 and a beta of 0.56. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The business’s 50-day simple moving average is $271.27 and its 200 day simple moving average is $294.21.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, sell-side analysts expect that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of analyst reports. Barclays lifted their price objective on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Truist Financial lifted their target price on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Morgan Stanley reduced their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday. Finally, Wells Fargo & Company reduced their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Humana has a consensus rating of “Hold” and an average target price of $293.05.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.